Clinical Trials Logo
  1. Home
  2. Gastro Esophageal Reflux
  3. NCT04202692

Effect of a Combination Oral Formulation of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate in Patients With Gastro-Esophageal Reflux Disease Not Fully Satisfied With Their Treatment

Gastro Esophageal Reflux Clinical Trial

Official title:
Evaluation of the Performance and Safety of an Oral Formulation of Hyaluronic Acid With Chondroitin Sulphate and Magnesium Trisilicate (GERDOff® Plus) in Patients With Gastro-Esophageal Reflux Disease: A Double-blind, Placebo-controlled, Randomized, Cross-over Study

Clinical Trial Summary

This is a post-market, multi-center, double-blind, placebo-controlled, randomized, cross-over study with GERDOff Plus added on top of the current PPI treatment in patients with GERD. The aim of the study is to evaluate the performance of GERDOff Plus, a class III medical device, consisting in a hyaluronic acid, chondroitin sulphate and magnesium trisilicate, in addition to the PPIs, in patients with GERD not fully satisfied with their current treatment with PPIs. Patients will receive either GERDOff Plus or placebo q.i.d. for 21 days followed by a wash-out period of 3 weeks. After the wash-out period, the patients will receive either placebo or GERDOff Plus respectively

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04202692
Study type Interventional
Source SOFAR S.p.A.
Contact
Status Completed
Phase N/A
Start date November 5, 2019
Completion date November 23, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06025773 - A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121 Phase 1
Recruiting NCT06280664 - Efficacy Of Hiatal Closure For GERD
Recruiting NCT05359965 - Effect of CPAP on Abnormal Gastroesophageal Reflux and Lung Inflammation in IPF N/A
Active, not recruiting NCT03646045 - Transpyloric Feeding for Prevention of Micro-aspiration
Recruiting NCT06430047 - Efficacy and Safety of EsoDuo® Phase 4
Completed NCT04268719 - Near Focus NBI-Driven Artificial Intelligence for the Diagnosis of Gastro-Oesophageal Reflux Disease
Active, not recruiting NCT04614974 - Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia Phase 1/Phase 2
Terminated NCT05579444 - Systems Biology of Gastrointestinal and Related Diseases
Recruiting NCT03868267 - Japanese Upper GI Symptoms Compared With Iranian and Canadian Patients Presenting
Terminated NCT04028466 - Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features Phase 4
Active, not recruiting NCT05371717 - Domiciliary Management of Dental Erosion in Patients With GERD With Biomimetic Hydroxyapatite N/A
Recruiting NCT05066594 - Observational Registry of Transoral Incisionless Fundoplication (TIF) for Gastroesophageal Reflux Disease (GERD)
Completed NCT03476265 - Lower Esophageal Sphincter (LES) Stimulation in Patients With Ineffective Esophageal Motility N/A
Completed NCT03143608 - GERD Treatment With Transoral Incisionless Fundoplication (TIF) Following Hiatal Hernia Surgery N/A
Completed NCT04436159 - Partial Versus Total Fundoplication in the Surgical Repair of Para-esophageal Hernia. N/A
Completed NCT03258528 - Effect of Right Lateral Position on Ventilated Preterm Neonates N/A
Active, not recruiting NCT04500288 - The Effect of Positional Therapy on Symptoms of Gastroesophageal Reflux Disease: A Prospective Pilot Study N/A
Completed NCT04262648 - Randomized Placebo-controlled Study of L. Reuteri NCIMB 30351 in GI Functional Disorders and Food Allergy in Newborns N/A
Recruiting NCT04846010 - Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 Phase 1/Phase 2
Active, not recruiting NCT03835663 - The Bacterial Composition of the Stomach in Reflux Disease